Alaunos Therapeutics (TCRT) Competitors $2.16 +0.03 (+1.41%) (As of 10:55 AM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends TCRT vs. EGRX, NKGN, AKTX, PMCB, SLGL, WENA, AIM, NLSP, SNSE, and TLPHShould you be buying Alaunos Therapeutics stock or one of its competitors? The main competitors of Alaunos Therapeutics include Eagle Pharmaceuticals (EGRX), NKGen Biotech (NKGN), Akari Therapeutics (AKTX), PharmaCyte Biotech (PMCB), Sol-Gel Technologies (SLGL), ANEW Medical (WENA), AIM ImmunoTech (AIM), NLS Pharmaceutics (NLSP), Sensei Biotherapeutics (SNSE), and Talphera (TLPH). These companies are all part of the "pharmaceutical products" industry. Alaunos Therapeutics vs. Eagle Pharmaceuticals NKGen Biotech Akari Therapeutics PharmaCyte Biotech Sol-Gel Technologies ANEW Medical AIM ImmunoTech NLS Pharmaceutics Sensei Biotherapeutics Talphera Alaunos Therapeutics (NASDAQ:TCRT) and Eagle Pharmaceuticals (NASDAQ:EGRX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, institutional ownership, risk, dividends, earnings, profitability and community ranking. Does the MarketBeat Community prefer TCRT or EGRX? Eagle Pharmaceuticals received 405 more outperform votes than Alaunos Therapeutics when rated by MarketBeat users. Likewise, 67.87% of users gave Eagle Pharmaceuticals an outperform vote while only 58.33% of users gave Alaunos Therapeutics an outperform vote. CompanyUnderperformOutperformAlaunos TherapeuticsOutperform Votes758.33% Underperform Votes541.67% Eagle PharmaceuticalsOutperform Votes41267.87% Underperform Votes19532.13% Do institutionals and insiders have more ownership in TCRT or EGRX? 27.7% of Alaunos Therapeutics shares are held by institutional investors. Comparatively, 85.4% of Eagle Pharmaceuticals shares are held by institutional investors. 5.1% of Alaunos Therapeutics shares are held by company insiders. Comparatively, 28.9% of Eagle Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has more volatility & risk, TCRT or EGRX? Alaunos Therapeutics has a beta of -0.49, suggesting that its stock price is 149% less volatile than the S&P 500. Comparatively, Eagle Pharmaceuticals has a beta of 0.62, suggesting that its stock price is 38% less volatile than the S&P 500. Does the media refer more to TCRT or EGRX? In the previous week, Eagle Pharmaceuticals had 3 more articles in the media than Alaunos Therapeutics. MarketBeat recorded 3 mentions for Eagle Pharmaceuticals and 0 mentions for Alaunos Therapeutics. Alaunos Therapeutics' average media sentiment score of 0.00 equaled Eagle Pharmaceuticals'average media sentiment score. Company Overall Sentiment Alaunos Therapeutics Neutral Eagle Pharmaceuticals Neutral Which has higher valuation & earnings, TCRT or EGRX? Eagle Pharmaceuticals has higher revenue and earnings than Alaunos Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlaunos TherapeuticsN/AN/A-$35.14MN/AN/AEagle Pharmaceuticals$316.61M0.03$35.64MN/AN/A Is TCRT or EGRX more profitable? Eagle Pharmaceuticals' return on equity of 0.00% beat Alaunos Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Alaunos TherapeuticsN/A -267.77% -209.18% Eagle Pharmaceuticals N/A N/A N/A SummaryEagle Pharmaceuticals beats Alaunos Therapeutics on 10 of the 10 factors compared between the two stocks. Ad Wyatt Investment ResearchMy #1 Pre IPO Trade for 2025 – NAME and TICKEROne tiny company... Could quickly become "the next SpaceX." It plans to go public on the NASDAQ. And today you can buy Pre-IPO shares for less than $4.00. Get urgent details inside this free report...The Next SpaceX Pre-IPO Get Alaunos Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TCRT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TCRT vs. The Competition Export to ExcelMetricAlaunos TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.46M$6.48B$5.08B$8.80BDividend YieldN/A8.11%5.02%4.07%P/E RatioN/A4.9791.2813.60Price / SalesN/A371.451,226.2187.40Price / CashN/A52.5939.4536.27Price / Book1.2710.306.906.33Net Income-$35.14M$153.61M$118.83M$225.93M7 Day Performance-6.09%-1.73%-1.92%-0.96%1 Month Performance-1.37%-7.26%-3.75%1.06%1 Year Performance-80.62%31.10%31.37%26.59% Alaunos Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TCRTAlaunos TherapeuticsN/A$2.16+1.4%N/A-81.3%$3.46MN/A0.0040EGRXEagle Pharmaceuticals1.1042 of 5 stars$0.65flatN/A-92.5%$8.47M$316.61M0.00134Analyst ForecastNKGNNKGen BiotechN/A$0.39+24.6%N/A-89.1%$13.79M$80,000.00-0.06N/AGap UpAKTXAkari TherapeuticsN/A$1.11-24.5%N/A-55.0%$13.49MN/A0.009Analyst ForecastNews CoverageHigh Trading VolumePMCBPharmaCyte Biotech0.6488 of 5 stars$1.68-2.3%N/A-21.1%$12.90MN/A2.612SLGLSol-Gel Technologies3.6128 of 5 stars$0.45+2.0%$5.00+1,011.1%-68.5%$12.54M$1.55M-1.3050News CoverageGap DownWENAANEW MedicalN/A$0.73-0.5%N/AN/A$12.51MN/A0.00N/AGap UpAIMAIM ImmunoTech1.7374 of 5 stars$0.20-2.4%$3.00+1,436.1%-52.0%$12.44M$200,000.000.0020News CoverageNLSPNLS Pharmaceutics1.2066 of 5 stars$3.23-1.8%N/A+623.1%$12.34MN/A0.006Gap DownSNSESensei Biotherapeutics4.8056 of 5 stars$0.49-1.9%$4.33+786.7%-20.0%$12.29MN/A0.0040News CoverageTLPHTalphera2.6915 of 5 stars$0.72+1.8%$4.50+525.8%N/A$12.25M$650,000.000.0019Gap Up Related Companies and Tools Related Companies Eagle Pharmaceuticals Alternatives NKGen Biotech Alternatives Akari Therapeutics Alternatives PharmaCyte Biotech Alternatives Sol-Gel Technologies Alternatives ANEW Medical Alternatives AIM ImmunoTech Alternatives NLS Pharmaceutics Alternatives Sensei Biotherapeutics Alternatives Talphera Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TCRT) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alaunos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alaunos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
